ANTIGENIC VARIATION OF HIV-1 AND RELATED LENTIVIRUSES

HIV-1 和相关慢病毒的抗原变异

• 批准号: 2295839
• 负责人: DAVID D HO
• 金额: $ 80.45万
• 依托单位: AARON DIAMOND AIDS RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-06-30 至 1998-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2295839
• 关键词: ANTIGENIC; VARIATION; HIV; RELATED; LENTIVIRUSES

HIV evolves rapidly and strains with widely divergent nucleotide sequences have been isolated from a number of geographic locations. Detailed information on the number of distinguishable HIV serotypes circulating within different communities is lacking and, because the mechanisms for inducing protective immunity are unknown, it is not known whether effective AIDS vaccine preparations will need to contain immunogenic material derived from viral variants geographically associated with the target population or with phases of the epidemic. Thus, there is a need to monitor genetic and antigenic variation of HIV in selected geographical locations which, in turn, will allow assessment of the impact of this variation on vaccine efficacy. HIV vaccine efficacy trials are currently being planned that would be carried out at both domestic and international sites. While it may not be possible to tailor the initial vaccines that will be tested in these early trials to the major virus strain present at each site, it will be of considerable interest to identify the major virus genotypes/serotypes/immunotypes present at these sites in order to analyze efficacy of the test vaccines. The NIAID currently supports research aimed at identifying the major genotypes of HIV that exist in the world, including the funding of both a genetic cloning and sequencing laboratory and an HIV sequence database and analysis unit. there is now a need to correlate antigenic properties of the virus with genetic data. The contractor will be provided with specimens by investigators, identified by the Project Officer, who are operating in geographical areas where vaccine trials may potentially occur. It is hoped that data resulting from this contract will permit informed decisions regarding virus type(s) to which vaccines should be modeled and will aid in the assessment of vaccine efficacy at those sites.

HIV迅速发展，并具有广泛不同的核苷酸菌株 序列已从许多地理位置中分离出来。 有关可区分HIV血清型数量的详细信息 缺乏在不同社区中流通的，因为 诱导保护性免疫的机制尚不清楚，尚不清楚 有效的艾滋病疫苗准备是否需要包含 从地理上衍生出病毒变异的免疫原料 与目标人群或流行病相关。 因此，需要监测HIV的遗传和抗原变异 在选定的地理位置中，该地点又将允许评估 这种变异对疫苗功效的影响。 目前正在计划进行HIV疫苗疗效试验 在国内和国际地点进行。 虽然可能不是 可以调整将在这些中测试的初始疫苗 早期试验每个位点存在的主要病毒菌株，将是 识别主要病毒的兴趣很大 基因型/血清型/免疫型在这些位置，以便为了 分析测试疫苗的功效。 NIAID目前支持 旨在确定艾滋病毒的主要基因型的研究 世界，包括遗传克隆和测序的资金 实验室和HIV序列数据库和分析单元。 现在有 需要将病毒的抗原特性与遗传数据相关联。 调查人员将为承包商提供标本 由项目官员确定，他们在地理上运作 可能会进行疫苗试验的区域。 希望数据 该合同产生的将允许有关有关的明智决定 应该对疫苗进行建模的病毒类型，并将有助于 评估这些部位的疫苗功效。